JP2012500245A5 - - Google Patents

Download PDF

Info

Publication number
JP2012500245A5
JP2012500245A5 JP2011523405A JP2011523405A JP2012500245A5 JP 2012500245 A5 JP2012500245 A5 JP 2012500245A5 JP 2011523405 A JP2011523405 A JP 2011523405A JP 2011523405 A JP2011523405 A JP 2011523405A JP 2012500245 A5 JP2012500245 A5 JP 2012500245A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
hydromethanesulfonate
hydromaleate
hydrofumarate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500245A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/060592 external-priority patent/WO2010020602A1/en
Publication of JP2012500245A publication Critical patent/JP2012500245A/ja
Publication of JP2012500245A5 publication Critical patent/JP2012500245A5/ja
Pending legal-status Critical Current

Links

JP2011523405A 2008-08-19 2009-08-17 経皮的インターベンション心臓カテーテル法のためのダビガトラン Pending JP2012500245A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9001808P 2008-08-19 2008-08-19
US61/090,018 2008-08-19
PCT/EP2009/060592 WO2010020602A1 (en) 2008-08-19 2009-08-17 Dabigatran for percutaneous interventional cardiac catheterisation

Publications (2)

Publication Number Publication Date
JP2012500245A JP2012500245A (ja) 2012-01-05
JP2012500245A5 true JP2012500245A5 (enExample) 2012-10-04

Family

ID=41258283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523405A Pending JP2012500245A (ja) 2008-08-19 2009-08-17 経皮的インターベンション心臓カテーテル法のためのダビガトラン

Country Status (19)

Country Link
US (1) US20110301201A1 (enExample)
EP (1) EP2328580A1 (enExample)
JP (1) JP2012500245A (enExample)
KR (1) KR20110044230A (enExample)
CN (1) CN102123707A (enExample)
AR (1) AR073077A1 (enExample)
AU (1) AU2009284217A1 (enExample)
BR (1) BRPI0917507A2 (enExample)
CA (1) CA2734794A1 (enExample)
CL (1) CL2011000361A1 (enExample)
CO (1) CO6290686A2 (enExample)
EA (1) EA201100358A1 (enExample)
EC (1) ECSP11010825A (enExample)
IL (1) IL210005A0 (enExample)
MA (1) MA32563B1 (enExample)
MX (1) MX2011001612A (enExample)
NZ (1) NZ591108A (enExample)
TW (1) TW201022235A (enExample)
WO (1) WO2010020602A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358368A1 (en) 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
CA2791561A1 (en) * 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420984B (zh) * 2012-05-24 2015-07-08 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420982B (zh) * 2012-05-24 2015-07-08 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420985B (zh) * 2012-05-24 2015-09-23 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559B (zh) * 2012-07-05 2016-09-28 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
IN2015DN02601A (enExample) * 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
DK2968297T3 (en) 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485094B2 (de) * 2002-03-07 2020-03-25 Boehringer Ingelheim International GmbH Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
JP2008517974A (ja) * 2004-10-25 2008-05-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用
CA2657270A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New paediatric indications for direct thrombin inhibitors
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester

Similar Documents

Publication Publication Date Title
US9809545B2 (en) Factor XIa inhibitors
TWI359140B (enExample)
JP2007537187A5 (enExample)
CA2674436A1 (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
US9777002B2 (en) Inhibitors of the renal outer medullary potassium channel
TWI388345B (zh) 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型
US10173998B2 (en) Antifungal compound process
JP2009514837A5 (enExample)
US20080200514A1 (en) Indications for Direct Thrombin Inhibitors
JP2010515715A5 (enExample)
KR101775304B1 (ko) 퀴놀론 화합물의 제조 방법
JP2017528494A (ja) ｓＧＣ刺激剤
JP2006523216A5 (enExample)
NZ592508A (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
US20190177298A1 (en) Antifungal Compound Process
US20150322056A1 (en) Factor IXa Inhibitors
JP2009510064A5 (enExample)
JP2014532754A5 (enExample)
JP2010516700A5 (enExample)
CA2657266A1 (en) New indications for direct thrombin inhibitors in the cardiovascular field
CN115315423A (zh) 取代芳基类化合物
WO2008009210A8 (fr) Composés de dihydropyrimidine optiquement purs et leurs utilisations dans la fabrication d'un médicament pour traiter ou prévenir des viroses
EP2765860A1 (en) Mineralocorticoid receptor antagonists
US20250243228A1 (en) PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS
JP2011500575A5 (enExample)